SCIENCE IN THE NEWS DAILY
Promising Alzheimer's Drug Approved for Late-Stage Trials
from USA Today
An experimental drug for Alzheimer's disease patients showed promise in Phase II clinical trials and is moving into final-stage trials, Wyeth and Elan, the makers of bapineuzumab, announced Tuesday.
Bapineuzumab is designed to fight beta amyloid, a toxic protein that clumps together in the brains of Alzheimer's patients.
In the early studies, conducted around the USA, 240 people with early- to moderate-stage Alzheimer's disease were either assigned bapineuzumab or a placebo. Researchers reported that non-carriers of a gene considered to be a risk factor for Alzheimer's disease, called ApoE4, showed "clinically meaningful benefits" in a battery of tests used to track the progression of Alzheimer's disease.
Read more ...
Connect With Us:
VIDEO: The Promise and Peril of Drones
The automation of tasks at work and at home is just around the corner, including driving cars, piloting planes, delivering packages, and transporting weapons. Unmanned aerial vehicles are rapidly evolving to meet both society’s and the military’s needs in automation and better efficiency.
During her time as one of the first female fighter pilots in the US Navy, Dr. Missy Cummings observed that computers could take off and land a plane more precisely than humans. Because of this breakthrough and her fascination with this growing technology, she began human–drone interaction research.
To view all multimedia content, click "Latest Multimedia."
Receive notification when new content is posted from the entire website, or choose from the customized feeds available.